Contact Us
Posted: May 16, 2017
  • Company News

Abingdon Health CTO chairs sessions at Bio-Sensing Technology Conference

Abingdon Health’s Chief Technology Officer recently participated in the 5th Bio-sensing Technology Conference in Lake Garda, Italy, as a member of the Scientific Committee.

The event, which happens bi-annually, brings together trusted voices from industry and academia to share their knowledge and experiences with the aim of developing and exploiting new technology for bio-sensing applications.

As well as chairing conference sessions, Abingdon Health’s Chief Technology Officer was involved in judging both poster and oral sessions which were of an extremely high standard. Much of the conference content was directly relevant to Abingdon Health’s business and discussions with other attendees are likely to result in further collaborations.

Bio-sensing technology

Bio-sensing technologies are growing in importance and the benefits of such technologies are being realised by many industry sectors. With events such as the International Conference on Bio-Sensing Technology taking place, this technology is set to improve further as experts discuss some of the main challenges and open up new possibilities where beneficiaries will receive improved rapid diagnostic results and services.

Abingdon Health is involved in this ever-evolving landscape and is currently collaborating with Cambridge Display Technology Limited (“CDT”), a Sumitomo Chemical Group Company; to develop a next-generation multiplexed rapid diagnostics biosensor.

Like many products in society, the market demands them to be efficient, multi-functional, quick and compact. The mobile phone market is probably the best example of compact, multi-functionality market demand. The rapid diagnostics market is no different.

Detection of some biomarkers requires quantification owing to the marker-ratio in a sample being important for determining the stage of the disease or condition. Combined lateral flow and assay reader technology can provide this quantitative requirement. The next generation of near-patient testing will aim to combine the need for detecting multiple markers quickly, on one hand-held or compact multiplexed-biosensor, with the ability to produce multiplexed quantitative results in minutes.